tetano
Editor, Senior Moderator
J Neurol
. 2020 Jun 3.
doi: 10.1007/s00415-020-09944-8. Online ahead of print.
COVID-19 in Teriflunomide-Treated Patients With Multiple Sclerosis
Amir Hadi Maghzi[SUP] 1 [/SUP], Maria K Houtchens[SUP] 1 [/SUP], Paolo Preziosa[SUP] 2 [/SUP], Carolina Ionete[SUP] 3 [/SUP], Biljana D Beretich[SUP] 4 [/SUP], James M Stankiewicz[SUP] 1 [/SUP], Shahamat Tauhid[SUP] 1 [/SUP], Ann Cabot[SUP] 5 [/SUP], Idanis Berriosmorales[SUP] 3 [/SUP], Tamara H W Schwartz[SUP] 4 [/SUP], Jacob A Sloane[SUP] 6 [/SUP], Mark S Freedman[SUP] 7 [/SUP], Massimo Filippi[SUP] 2 8 [/SUP], Howard L Weiner[SUP] 1 [/SUP], Rohit Bakshi[SUP] 9 [/SUP]
Affiliations
Abstract
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
Keywords: Antiviral; COVID-19; Coronavirus; Multiple sclerosis; Teriflunomide.
. 2020 Jun 3.
doi: 10.1007/s00415-020-09944-8. Online ahead of print.
COVID-19 in Teriflunomide-Treated Patients With Multiple Sclerosis
Amir Hadi Maghzi[SUP] 1 [/SUP], Maria K Houtchens[SUP] 1 [/SUP], Paolo Preziosa[SUP] 2 [/SUP], Carolina Ionete[SUP] 3 [/SUP], Biljana D Beretich[SUP] 4 [/SUP], James M Stankiewicz[SUP] 1 [/SUP], Shahamat Tauhid[SUP] 1 [/SUP], Ann Cabot[SUP] 5 [/SUP], Idanis Berriosmorales[SUP] 3 [/SUP], Tamara H W Schwartz[SUP] 4 [/SUP], Jacob A Sloane[SUP] 6 [/SUP], Mark S Freedman[SUP] 7 [/SUP], Massimo Filippi[SUP] 2 8 [/SUP], Howard L Weiner[SUP] 1 [/SUP], Rohit Bakshi[SUP] 9 [/SUP]
Affiliations
- PMID: 32494856
- DOI: 10.1007/s00415-020-09944-8
Abstract
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
Keywords: Antiviral; COVID-19; Coronavirus; Multiple sclerosis; Teriflunomide.